#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14578	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2116	683.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1438	1438	C	849	C	803	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26700	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3620	735.3	0	.	n	.	0	T695C	SNP	695	695	T	1089	1089	C	779	C,T	733,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26700	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3620	735.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1731	1731	A	867	A	820	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26700	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3620	735.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2365	2365	C	868	C,G	807,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26700	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3620	735.3	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2991	2991	T	857	T	811	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26700	23S	2890	2890	99.86	23S.l6.c30.ctg.1	3620	735.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2439	2439	A	854	A	811	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2254	folP	855	855	100.0	folP.l15.c4.ctg.1	1570	142.9	1	SNP	p	R229S	1	.	.	685	687	AGC	1063	1065	AGC	240;239;237	A;G;C	221;222;219	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5844	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3562	163.8	1	SNP	p	S91F	1	.	.	271	273	TTC	684	686	TTC	192;192;193	T;T;C	180;180;182	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5844	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3562	163.8	1	SNP	p	D95G	1	.	.	283	285	GGC	696	698	GGC	187;188;183	G;G,A;C	178;176,1;173	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5844	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3562	163.8	1	SNP	p	G95N	0	.	.	283	285	GGC	696	698	GGC	187;188;183	G;G,A;C	178;176,1;173	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_X_01389	mtrR.WHO_X_01389	1	1	27	1768	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1401	125.8	1	SNP	p	G45D	0	.	.	133	135	GGC	537	539	GGC	209;211;217	G;G;C	196;201;204	mtrR.WHO_X_01389:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	872	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1063	81.6	0	.	n	.	0	A197.	DEL	197	197	A	564	564	A	217	A	203	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3091	161.4	1	SNP	p	D86N	0	.	.	256	258	GAC	705	707	GAC	213;213;213	G;A;C	199;195;200	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3091	161.4	1	SNP	p	S87R	1	.	.	259	261	CGT	708	710	CGT	213;214;214	C,T;G;T	199,1;200;199	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3091	161.4	1	SNP	p	R87I	0	.	.	259	261	CGT	708	710	CGT	213;214;214	C,T;G;T	199,1;200;199	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3091	161.4	1	SNP	p	R87W	0	.	.	259	261	CGT	708	710	CGT	213;214;214	C,T;G;T	199,1;200;199	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4996	parC	2304	2304	100.0	parC.l6.c30.ctg.1	3091	161.4	1	SNP	p	S88P	0	.	.	262	264	TCC	711	713	TCC	211;213;214	T;C;C,T	197;198;200,1	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4424	parE	1986	1986	100.0	parE.l6.c17.ctg.1	2643	166.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1583	1585	GGC	230;225;224	G;G;C	213;209;206	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1287	1289	GCA	200;200;203	G;C;A	184;188;190	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1290	1292	ATC	205;205;203	A;T;C	193;193;192	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1302	1304	GTG	214;216;213	G;T;G	199;199;198	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1302	1304	GTG	214;216;213	G;T;G	199;199;198	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1806	1808	ACC	199;199;194	A;C;C	188;184;183	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1860	1862	GCG	183;187;190	G;C,G;G	165;150,1;160	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1860	1862	GCG	183;187;190	G;C,G;G	165;150,1;160	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	G543S	1	.	.	1627	1629	AGC	1983	1985	AGC	188;188;187	A;G;C	176;177;175	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1992	1994	GGC	181;182;183	G;G;C	170;171;169	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4046	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2450	164.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2010	2012	CCG	158;162;164	C,G;C,G;GCCC,GGCCCC	124,2;126,1;123,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5706	ponA	2397	2397	100.0	ponA.l15.c30.ctg.1	3038	187.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1551	1553	CCG	209;209;211	C;C;G,C	192;197;193,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2492	porA	1146	1146	99.91	porA.l15.c30.ctg.1	1998	124.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	636	636	C	173	C	156	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	V75I	NONSYN	223	225	GTT	565	567	ATT	230;230;234	A;T;T	218;220;225	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	T89S	NONSYN	265	267	ACC	607	609	AGC	212;211;209	A;G;C,A	198;198;192,1	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	V98I	NONSYN	292	294	GTC	634	636	ATC	210;205;201	A;T;C	190;186;185	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	.	MULTIPLE	358	359	AA	699	700	CG	203;200	C;G,A	190;187,1	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	.	MULTIPLE	361	362	GA	702	704	CAG	198;198;198	C;A;G	187;189;189	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	N122K	NONSYN	364	366	AAC	706	708	AAA	198;199;196	A;A;A	190;192;188	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	733	735	TAT	204;205;205	T;A;T	200;201;197	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	N134E	NONSYN	400	402	AAT	742	744	GAG	201;200;202	G;A;G	197;195;196	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	V135L	NONSYN	403	405	GTG	745	747	CTT	202;203;205	C;T;T	199;198;199	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	G140K	NONSYN	418	420	GGA	760	762	AAA	208;208;208	A;A;A	200;200;200	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	Q143E	NONSYN	427	429	CAA	769	771	GAA	205;204;206	G;A;A	200;198;196	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	A213S	NONSYN	637	639	GCA	979	981	TCA	223;221;223	T;C;A	216;214;216	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	Y255W	NONSYN	763	765	TAC	1105	1107	TGG	239;238;240	T;G;G,A	226;227;223,1	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	R256H	NONSYN	766	768	CGT	1108	1110	CAT	239;238;237	C;A;T	221;225;224	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	0	.	p	.	0	E326A	NONSYN	976	978	GAA	1318	1320	GCA	200;201;206	G;C,A;A	191;191,1;192	.	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	1	SNP	p	G120K	1	.	.	358	360	AAG	699	701	CGG	203;200;196	C;G,A;G	190;187,1;185	porB1b.WHO_X_02194c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	1	SNP	p	D121N	0	.	.	361	363	GAC	702	705	CGC	198;198;200	C;G;C	187;189;188	porB1b.WHO_X_02194c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_X_02194c	porB1b.WHO_X_02194c	1	1	539	2724	porB1b	1041	1041	97.31	porB1b.l6.c17.ctg.1	1724	157.3	1	SNP	p	A121D	1	.	.	361	363	GAC	702	705	CGC	198;198;200	C;G;C	187;189;188	porB1b.WHO_X_02194c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9992	rpoB	4179	4179	99.98	rpoB.l6.c30.ctg.1	4946	201.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1114	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1042	106.3	1	SNP	p	V57M	1	.	.	169	171	ATG	521	523	ATG	217;219;220	A;T;G	208;209;210	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
